



NEWS RELEASE

Shareholder Notification

Liege (Belgium) – August 18, 2009, 18:00 CET – OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that it has received the following shareholder notifications covering changes to the Transparency Declaration of the Company:

- ING Investment Management Luxembourg S.A. holds more than 5% of the shares of the company
- ING Fund Management B.V. holds more than 3% of the shares of the company

The OncoMethylome shares held by the above entities together with those held by the ING Securities Investment & Trust Company had previously been reported jointly as ING Investment Management shareholdings. They will now be reported separately pursuant to the required legal shareholding thresholds. The shareholding by ING Belgium SA remains unchanged and is reported separately.

For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com

About OncoMethylome Sciences

OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome Sciences SA boasts a broad product development pipeline consisting of over ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, Exact Sciences Corp, Merck KGaA, and Qiagen. OncoMethylome Sciences' products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome Sciences SA has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Philip Devine
Tel. +32-479-505-885
ir@oncomethylome.com
www.oncomethylome.com